Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about HYPD, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
HYPD holds $6.6M in cash and short-term investments (as of Sep 30, 2026) and burns about $2.3M/quarter from operations, an estimated runway of 8.7 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 75 · High
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when HYPD files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Hyunsu Jung Chief Executive Officer and Chief Invest |
Insider | 1,345,676 | 8.69% | 2026-08-16 |
| David R. Knox Chief Financial Officer |
Insider | 287,556 | 1.86% | 2026-09-29 |
| Happy David Walters Director |
Insider | 170,847 | 1.10% | 2026-06-30 |
| Ellen R Strahlman Director |
Insider | 150,078 | 0.97% | 2026-06-30 |
| Michael S Geltzeiler Director |
Insider | 146,932 | 0.95% | 2026-06-30 |
| Rachel Jacobson Director |
Insider | 115,218 | 0.74% | 2026-06-30 |
| Robert Rubenstein General Counsel |
Insider | 75,000 | 0.48% | 2026-01-12 |
| Avenue Capital Management II, L.P. 10% owner |
Insider | 30,619 | 0.20% | 2025-02-21 |
| Tsontcho Ianchulev Director |
Insider | 17,780 | 0.11% | 2025-04-21 |
| Charles E Iv Mather Director |
Insider | 9,950 | 0.06% | 2025-04-21 |
| Michael M Rowe Chief Executive Officer, Director |
Insider | 7,975 | 0.05% | 2025-06-13 |
| Ram Palanki Director |
Insider | 4,235 | 0.03% | 2025-04-21 |
Share count 15,488,133 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for HYPD and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →